Photo: National Cancer Institute / Unsplash. Illustrative image; no endorsement implied.
You may be thinking about stopping Wegovy or Zepbound because of cost, side effects, a change in insurance, pregnancy plans, or simply reaching a weight that feels right for you. The question is reasonable: what happens next?
Weight regain is common after these medications are stopped, but a study average is not a prediction for one person. Withdrawal studies show that continuing treatment generally maintains weight loss better than stopping. That makes the transition worth planning with your prescriber before your supply runs out. [2] [3]
This article explains the main evidence and offers a conversation guide for your next appointment. It focuses on weight management, not instructions for changing a prescription. The trials below studied adults without diabetes using weekly semaglutide 2.4 mg or tirzepatide 10 or 15 mg; their findings should not be assumed to apply identically to every dose or formulation. [1] [3]
What the stopping studies actually found
Wegovy and the STEP 1 extension
In a follow-up involving 327 participants, the semaglutide group had lost an average of 17.3% of their original body weight after 68 weeks. One year after treatment ended, they had regained 11.6 percentage points of that original weight—roughly two-thirds of the weight previously lost. They remained about 5.6% below their starting weight on average. [1]
An important limitation: structured lifestyle support ended along with the medication. This was also a selected follow-up group, rather than everyone in the original trial. Many improvements in blood pressure and metabolic measures moved back toward pretreatment values; the study did not establish an individual’s future heart attack risk. [1]
Wegovy and the STEP 4 trial
STEP 4 helps address the lifestyle-support question. After 20 weeks on semaglutide, 803 participants were assigned either to continue treatment or switch to placebo. Both groups continued lifestyle counseling. Over the following 48 weeks, those continuing semaglutide lost another 7.9%, while those switched to placebo gained 6.9%. These percentages use weight at the time of the switch as the starting point. [2]
This supports a medication effect beyond the counseling provided in that trial. It does not mean food choices or physical activity are pointless, and it does not test every possible maintenance program. [2]
Zepbound and the SURMOUNT 4 trial
After 36 weeks on tirzepatide, 670 participants had lost an average of 20.9% of their starting weight. During the next 52 weeks, those continuing tirzepatide lost another 5.5%, while those switched to placebo gained 14.0% relative to their weight at the switch. [3]
That 14% is not 14% of the pounds previously lost. As a simple arithmetic example, gaining 14% from 200 pounds means gaining 28 pounds. The trial does not say that someone who lost 40 pounds would regain only 5.6 pounds. [3]
These trials were funded by the manufacturers. The randomized withdrawal studies also selected people who had completed the initial treatment period, which limits how well the results represent everyone who starts medication. [1] [2] [3]
What newer evidence adds
A systematic review published in The BMJ in 2026 examined 37 studies involving 9,341 participants across weight-management medications. It reinforced the pattern of regain after stopping. However, the newer-drug studies had no more than 12 months of follow-up after discontinuation, according to the publisher’s summary. [6]
Claims that everyone will return to their starting weight by a particular month go beyond what those observations can establish. Longer-term estimates rely on modeling, studies differ in quality and design, and individual outcomes vary. This evidence is a reason to arrange follow-up, not a personal countdown. [6]
Will hunger return immediately
These medicines affect appetite and food intake. As their effects diminish after stopping, you may notice appetite changes. The withdrawal trials discussed here primarily tell us about weight over months; they do not give a reliable day-by-day timetable for hunger or food cravings. [4] [5]
For your appointment, make the change concrete: Are you hungrier between meals? Thinking about food more often? Eating larger portions? Finding your usual routine harder to maintain? Those observations can help you describe what is happening without treating every difficult day as a failure.
Should you taper instead of stopping
The major withdrawal studies above do not establish a tapering schedule that prevents regain. Their findings should not be turned into a do-it-yourself plan to reduce doses or stretch injections farther apart. [2] [3]
Ask your prescriber whether the appropriate next step is continued treatment, a different prescribed maintenance dose, another treatment, or discontinuation. The reason for stopping matters. A planned change because of cost calls for a different conversation from suspected serious side effects or pregnancy.
Restarting deserves its own instructions. The current Wegovy injection label directs restarting dose escalation at a lower dose after two or more consecutive missed doses to reduce gastrointestinal problems. After a longer interruption of either medicine, ask your prescriber how to resume; do not assume your previous dose is still appropriate. [4]
Make a plan before the last dose
You do not need a perfect spreadsheet. A short written plan should answer five practical questions.
1 What is making treatment difficult
Write down the main issue: affordability, availability, symptoms, a health change, or your treatment preferences. If insurance is the problem, bring the denial or coverage notice. If side effects are the problem, describe their timing, severity, and effect on eating and drinking. That information makes the appointment more useful than simply saying the medication is not working for you.
2 What options are realistic
Ask which options fit your medical history and budget, what each would cost, and what the next step would be if the first choice is unavailable. Ask whether an insurance appeal or a different covered treatment is appropriate. Request a specific plan rather than leaving with a vague instruction to call if you have trouble.
3 What will you monitor
Agree on what to track, how often, and what should trigger a call. Possible discussion points include weight trends, appetite, symptoms, blood pressure, and blood glucose if relevant to your care. Ask which measurements actually matter for you and whether any other medications need review. Avoid choosing your own laboratory schedule or changing diabetes medicines based on this article.
4 What support will you keep
Bring your current eating and activity routine to the discussion. Ask whether a registered dietitian could help adapt meals as appetite changes, and whether your strength and activity plan suits your health and abilities. Be specific about constraints such as shift work, limited cooking time, food costs, pain, or mobility. The plan needs to fit the life you actually live.
For ideas to discuss, see HCW’s high-protein, high-fiber meal-planning guide and GLP-1 muscle-preservation checklist. These resources do not replace an individualized treatment plan.
5 When will you check back
Before leaving, confirm a follow-up date, who to contact between visits, and the agreed response if weight or symptoms change. Save the instructions somewhere easy to find. A useful question is: “If this plan is not working for me, what should I do next, and how soon should I contact you?”
When stopping requires prompt medical advice
For weight-management use, the labels instruct discontinuation when pregnancy is recognized. Wegovy should be stopped at least two months before a planned pregnancy. Contact your prescriber promptly to arrange care. [4] [5]
Severe or persistent abdominal pain, especially with vomiting or pain extending to the back, needs urgent medical assessment. Suspected pancreatitis requires stopping the medication. Trouble breathing or swelling of the face or throat calls for emergency care and stopping the medicine because of possible serious allergy. Persistent vomiting or inability to keep fluids down also warrants prompt assessment. [5]
The next step
If you are considering stopping, bring one clear request to your prescriber: “Help me make a plan for what happens after my last dose.” Include why you want or need to stop, what support you can realistically use, and how you will stay in contact. You deserve a workable follow-up plan, including a way to revise it.
This article provides general education and is not personal medical advice. Medication decisions should be made with your treating clinician.
Sources
1. STEP 1 extension. Wilding and colleagues, 2022.
2. STEP 4 randomized trial. Rubino and colleagues, 2021.
3. SURMOUNT-4 randomized trial. Aronne and colleagues, 2024.
4. Wegovy prescribing information. Novo Nordisk, revised June 2026.
5. Zepbound prescribing information. Eli Lilly, revised August 2026.
6. BMJ publisher summary of the weight regain review. Publisher summary of West and colleagues, BMJ 2026;392:e085304.